Distinct clinical profiles of nongonococcal gram-negative septic arthritis: a retrospective analysis from a tertiary center

非淋球菌革兰氏阴性菌感染性关节炎的独特临床特征:来自三级中心的回顾性分析

阅读:3

Abstract

BACKGROUND: Septic arthritis is life-threatening, with gram-positive bacteria as the primary cause. However, gram-negative infections are more prevalent in Asia, often resulting in inadequate empirical therapy and higher mortality. The factors linked to gram-negative septic arthritis remain poorly understood. Our aim was to investigate the prevalence, clinical characteristics, and predictive factors of nongonococcal gram-negative septic arthritis in the northeastern region of Thailand. METHODS: We conducted a retrospective study by analyzing medical records from Srinagarind Hospital, a 1,500-bed university hospital in northeastern Thailand, covering the period from January 1, 2015, to October 24, 2024. RESULTS: A total of 194 patients were included, of whom 67 (34.5%) were infected with gram-negative bacteria. The most common causative agent was Burkholderia pseudomallei (11.3%), followed by Escherichia coli (7.2%). Patients with gram-negative septic arthritis had a greater risk of requiring intensive care unit (ICU) or semi-ICU admission. Multivariate analysis revealed that diabetes mellitus, pyuria, and the absence of bacteria on synovial fluid Gram-stain were significant risk factors for gram-negative septic arthritis. In contrast, hypertension and upper joint involvement were associated with septic arthritis caused by gram-positive bacteria. Additionally, we observed that gram-negative-infected patients were more likely to receive ineffective empirical antibiotics. CONCLUSIONS: This study revealed a greater prevalence of nongonococcal gram-negative septic arthritis in the northeastern region of Thailand. Several risk factors, along with distinct clinical and laboratory characteristics, have been identified, which may help guide the selection of empiric antibiotics for more effective treatment. CLINICAL TRIALS REGISTRY: Retrospectively registered at Thai Clinical Trials Registry. The study was reviewed and approved on 13/02/2025. TCTR identification number is TCTR20250213003.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。